前列腺素类药物的相关眶周病变

Prostaglandin-associated periorbitopathy

青光眼是全球仅次于白内障的第二位致盲性眼病。青光眼治疗主要是通过药物、激光、手术等手段降低眼压，从而延缓疾病的进程。前列腺素类药物目前已成为临床治疗青光眼的一线用药。随着临床应用的不断增多，其局部不良反应逐渐呈现，如结膜充血、睫毛变长、眶周皮肤及虹膜色素加深、睑缘炎、黄斑水肿等。由于人们对外形美观的关注程度日益提高，故近年来不断有相关研究报道由前列腺素类药物引起的眶周改变，包括上睑皮肤松弛下垂、上眼睑沟加深、眶脂肪萎缩、眼眶凹陷、下巩膜显露等，并将这些病变合称为前列腺素类药物相关眶周病变（PAP）。本文将对PAP的发病机制、表现及改善方法等进行综述，以供临床参考使用。

Glaucoma is one of the leading causes of blindness in the world, second to cataract. The treatment of glaucoma mainly includes drugs, laser and operation, which can slow down the progress of the disease. Prostaglandin is the first-line medication at present. With the constant promotion of clinical application, the local side effects have been found, such as conjunctival congestion, lash lengthening, periorbital and iris pigment deepening, blepharitis and macular edema. As people pay more attention to appearance, periorbitopathy caused by prostaglandin has been reported in recent years, including upper eyelid ptosis and dermatochalasis, deepening of the upper eyelid sulcus, periorbital fat loss, enophthalmos and inferior scleral exposure. The mechanism, performance and treatment methods of these prostaglandin-associated periorbitopathies are reviewed.